Ozempic requires attaching a new pen needle for each injection, while Wegovy has an integrated needle in its single-dose pen
Occurred in 8.8% of participants on 9 mg and 20.9% on 12 mg, compared to 0.7% on placebo Dose-dependent (higher dose, higher risk) Generally described as mild Rarely led to discontinuation Why this matters: Dysesthesia was not reported in the Phase 2 trial
Journal reference: Klausen MK, Justesen SK, Pedersen JN, et al
Since SGLT2 inhibitors are relatively new and available as brand only, cost should also be considered
The expiry of patents on clopidogrel (Plavix), an antiplatelet medicine marketed by Sanofi and Bristol Myers Squibb, in 2012 created major opportunity for Indian firms to quickly introduce affordable alternatives that became widely used in cardiovascular care